Categories: News

Shockwave Medical Announces Details for Conference Call Discussing Second Quarter 2023 Results and Participation in Upcoming Investor Conference

SANTA CLARA, Calif., July 18, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, will report financial results for the second quarter 2023 after market close on Monday, August 7, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

On Wednesday, August 9, 2023, at 3:30 p.m. Eastern Time, Shockwave Medical management is scheduled to present at the Canaccord Genuity 43rd Annual Growth Conference, which is taking place from Monday, August 7 – Thursday, August 10, 2023 at the InterContinental Hotel in Boston, MA.

Interested parties may access live and archived webcasts of these events on the “Investors” section of the company’s website at https://ir.shockwavemedical.com. Investors interested in dialing in to the second quarter 2023 Shockwave Medical earnings conference call on Monday August 7, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time may do so by dialing 877-704-4453 for domestic callers or 201-389-0920 for international callers, using conference ID: 13737256.

About Shockwave Medical, Inc.

Shockwave Medical is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Shockwave has also recently acquired the Neovasc Reducer, which is under clinical investigation in the United States and is CE Marked in the European Union and the United Kingdom. By redistributing blood flow within the heart, the Reducer is designed to provide relief to the millions of patients worldwide suffering from refractory angina. Learn more at www.shockwavemedical.com and www.neovasc.com.

Media Contact:
Scott Shadiow
+1.317.432.9210
sshadiow@shockwavemedical.com

Investor Contact:
Debbie Kaster
investors@shockwavemedical.com

 

Staff

Recent Posts

Digital Case Acceptance Platform Reports Record Data for Case Acceptance and Productivity After Months of Testing

AcceptCare Adds New Tool to Increase High-Value Treatments like Ortho DENVER, CO / ACCESSWIRE /…

1 hour ago

AscellaHealth Chairman and President Bill Oldham Named 2024 Philadelphia Titan 100

BERWYN, Pa.--(BUSINESS WIRE)--Titan CEO and headline sponsor Wipfli LLP are pleased to announce Bill Oldham, chairman…

4 hours ago

24-Provider Rockbridge Area Health Center Enhances Clinical Efficiency Using Sunoh.ai

The FQHC leverages eClinicalWorks EDR and AI-powered medical scribe to reduce physician burnout and improve…

4 hours ago

Osteotec announces strategic collaboration with Additive Surgical, bringing cutting-edge 3D-printed spine technology to the UK

NEWBURY, England, June 13, 2024 /PRNewswire/ -- Osteotec, the market-leading manufacturer and distributor of medical…

4 hours ago

ImpediMed Appoints Google Financial Executive Fiona Bones to Board of Directors

Google executive brings more than two decades of financial and management expertise to medical technology…

4 hours ago

EPAM Acquires Odysseus — to transform the Life Sciences Value Chain with Advanced Analytics, Data Methods and AI

Improving life sciences research, clinical studies and post-market surveillance powered by data and AI NEWTOWN,…

4 hours ago